ALNYLAM PHARMACEUTICALS, INC. 10-K

ITEM 2. PROPERTIES Our operations are based primarily in Cambridge, Massachusetts; Zug, Switzerland; Maidenhead, United Kingdom; Amsterdam, Netherlands; and Tokyo, Japan. A description of certain of the facilities we lease or own as of January 31, 2026 is included in the table below. Location Primary Use Approximate Square Footage Lease Expiration Date Renewal Option 675 West Kendall Street Henri A. Termeer Square Cambridge, Massachusetts Corporate headquarters and primary research facility 295,000 January 2034 Two five-year terms 300 Third Street Cambridge, Massachusetts Office space and additional research facility 129,000 January 2034 Two five-year terms 101 Main Street Cambridge, Massachusetts Office space 23,350 June 2029 Two two-year terms 20 Commerce Way Norton, Massachusetts GMP manufacturing 200,000 Owned Owned 665 Concord Avenue Cambridge, Massachusetts GMP manufacturing 15,000 September 2027 One five-year term Grafenauweg 2 & 4 6300 Zug, Switzerland International headquarters 15,800 May 2029 One five-year term 27 Market Street, Maidenhead Berkshire, United Kingdom Office space 15,600 October 2035 One five-year term Wisdom Cross Tower Antonio Vivaldistraat 150 Amsterdam, Netherlands Office space 12,500 April 2030 One five-year term Pacific Century Place 1-Chome-11-1 Marunouchi Chiyoda-ku Tokyo, Japan Office space 12,700 May 2028 None _________________________________________ In addition to the locations above, we also occupy small offices in multiple locations in and outside of the U.S. to support our operations and growth. In the future, we may lease, operate, purchase or construct additional facilities in which to conduct expanded research, development and manufacturing activities and support future commercial operations. We believe that the total space available to us under our current leases will meet our needs for the foreseeable future and that additional space would be available to us on commercially reasonable terms if required.